Clinical Trials and the Future of Lymphoma Treatment

1

Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials.

“Clinical trials really are the future of lymphoma treatment,” says Ann LaCasce, MD, a medical oncologist in the Adult Lymphoma Program at Dana-Farber/Brigham and Women’s Cancer Center.

Ann LaCasce, MD

Ann LaCasce, MD

Clinical trials have led to a number of improved therapies for both Hodgkin and non-Hodgkin lymphomas, including approved drugs like BrentuximabIbrutinib and Lenalidomide. Meanwhile, studies continue on other promising new drugs like Idelalisib.

LaCasce details many of these new drugs and future treatment options in her presentation, “Clinical Trials, Emerging New Drugs and Future Concepts of Treatment in Lymphoma.” The talk was given at the Lymphoma Research Foundation’s (LRF) North American Educational Forum in September 2013.

To view LaCasce’s presentation, visit the Dana-Farber Slideshare page.

View more presentations given at the LRF’s annual conference:

Comments Sort By Newest

One thought on “Clinical Trials and the Future of Lymphoma Treatment

  1. Dr. Ann, your comments about “mustard gas” are particularly timely considering some of the popular chatter about Bendamustine, essentially an old chemotherapy. I’m no expert, just one DFCI patient who has participated in a few Clinical Trials of emerging targeted therapies which I believe will prove to be safer and more effective than conventional chemotherapy. Just my opinion- cancer patients should engage his/her oncologist to explore what novel treatment options are available in Clinical Trials. As we travel the road to Personalized Medicine still under construction, genomics-based therapy rather than empirical therapy might be our best option. Jack

  2. Dr. Ann, your comments about “mustard gas” are particularly timely considering some of the popular chatter about Bendamustine, essentially an old chemotherapy. I’m no expert, just one DFCI patient who has participated in a few Clinical Trials of emerging targeted therapies which I believe will prove to be safer and more effective than conventional chemotherapy. Just my opinion- cancer patients should engage his/her oncologist to explore what novel treatment options are available in Clinical Trials. As we travel the road to Personalized Medicine still under construction, genomics-based therapy rather than empirical therapy might be our best option. Jack

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image
Refresh

*

Make An Appointment

For adults: 877-442-3324

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
What’s the Connection between Night Sweats and Cancer? https://t.co/sWhbry56jo #leusm #lymsm https://t.co/FSoudSn2sX
Dana-Farber @danafarber
High order drug combinations are required to effectively kill colorectal cancer cells: https://t.co/NHBb4nRu9W #crcsm via @AACR
Dana-Farber @danafarber
70% of patients need a marrow donor outside of family, join @BeTheMatch & DFCI Oct.1 12-2 @ McGlynn School in @MedfordMass #stemcell

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.